Protara Therapeutics, Inc.
TARA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001359931
In the last 90 days, Protara Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 119 institutions reported holding it in 13F filings for Q2 2026, worth $176.0M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Protara Therapeutics, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 35
- −3 vs. Q4 2021
- Shares held
- 6.50M
- −376.9K (−5.5%) vs. Q4 2021
- Total value
- $33.2M
- −$13.3M (−28.6%) vs. Q4 2021
- New holders
- 3
- 8 more added
- Sold out
- 6
- 17 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TARA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 119 | $176.0M |
| Q1 2026 | 114 | $237.4M |
| Q4 2025 | 105 | $212.3M |
| Q3 2025 | 81 | $114.0M |
| Q2 2025 | 76 | $90.1M |
| Q1 2025 | 59 | $123.8M |
| Q4 2024 | 60 | $156.6M |
| Q3 2024 | 35 | $19.1M |
| Q2 2024 | 38 | $22.2M |
| Q1 2024 | 34 | $18.3M |
| Q4 2023 | 30 | $8.17M |
| Q3 2023 | 31 | $8.55M |
| Q2 2023 | 29 | $12.3M |
| Q1 2023 | 29 | $16.9M |
| Q4 2022 | 30 | $14.7M |
| Q3 2022 | 31 | $16.7M |
| Q2 2022 | 33 | $18.4M |
| Q1 2022 | 35 | $33.2M |
| Q4 2021 | 38 | $46.5M |
| Q3 2021 | 36 | $43.7M |
| Q2 2021 | 40 | $69.3M |
| Q1 2021 | 50 | $134.0M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Protara Therapeutics, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Opaleye Management Inc. | 2,674,031 | $13.7M | 4.24% | +24,031+0.9% | Added |
| OrbiMed Advisors LLC | 830,641 | $4.25M | 0.07% | 00.0% | Unchanged |
| Vanguard Group Inc | 427,404 | $2.18M | 0.00% | −7,847−1.8% | Reduced |
| Citadel Advisors LLC | 406,248 | $2.08M | 0.00% | −22,118−5.2% | Reduced |
| Perceptive Advisors LLC | 383,526 | $1.96M | 0.04% | −38,115−9.0% | Reduced |
| Ikarian Capital, LLC | 296,426 | $1.51M | 0.46% | +17,170+6.1% | Added |
| DLD Asset Management, LP | 229,531 | $1.17M | 0.08% | +300+0.1% | Added |
| Boxer Capital, LLC | 209,227 | $1.07M | 0.05% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 199,671 | $1.02M | 0.01% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 152,847 | $781.0K | 0.00% | −44,455−22.5% | Reduced |
| Two Sigma Investments, LP | 88,779 | $454.0K | 0.00% | −101,499−53.3% | Reduced |
| Geode Capital Management, LLC | 81,964 | $418.0K | 0.00% | +2,947+3.7% | Added |
| Millennium Management LLC | 72,350 | $370.0K | 0.00% | −33,895−31.9% | Reduced |
| Two Sigma Advisers, LP | 65,918 | $337.0K | 0.00% | −105,000−61.4% | Reduced |
| Bridgeway Capital Management, LLC | 64,000 | $327.0K | 0.01% | +10,500+19.6% | Added |
| Assenagon Asset Management S.A. | 43,741 | $224.0K | 0.00% | +43,741 | New |
| BlackRock Inc. | 38,916 | $200.0K | 0.00% | −1,224−3.0% | Reduced |
| Renaissance Technologies LLC | 37,600 | $192.0K | 0.00% | −27,200−42.0% | Reduced |
| State Street Corp | 30,900 | $158.0K | 0.00% | +1,100+3.7% | Added |
| Dimensional Fund Advisors LP | 30,606 | $156.0K | 0.00% | −2,868−8.6% | Reduced |
| Boothbay Fund Management, LLC | 27,591 | $141.0K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 20,019 | $102.0K | 0.00% | −2,196−9.9% | Reduced |
| Bank of New York Mellon Corp | 17,907 | $92.0K | 0.00% | 00.0% | Unchanged |
| Trexquant Investment LP | 16,313 | $83.0K | 0.00% | +1,158+7.6% | Added |
| Susquehanna International Group, LLP | 13,739 | $70.0K | 0.00% | −14,123−50.7% | Reduced |
| Prelude Capital Management, LLC | 12,872 | $66.0K | 0.00% | −3,983−23.6% | Reduced |
| Acadian Asset Management LLC | 11,730 | $59.0K | 0.00% | −5,489−31.9% | Reduced |
| Morgan Stanley | 6,556 | $33.0K | 0.00% | −21,344−76.5% | Reduced |
| Barclays PLC | 2,510 | $13.0K | 0.00% | +2,510 | New |
| Bank of America Corp | 745 | $3.00K | 0.00% | −6,133−89.2% | Reduced |
| Wells Fargo & Company | 560 | $3.00K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 574 | $3.00K | 0.00% | +574 | New |
| Federated Hermes, Inc. | 426 | $2.00K | 0.00% | +296+227.7% | Added |
| Royal Bank of Canada | 146 | $1.00K | 0.00% | −13−8.2% | Reduced |
| American Portfolios Advisors | 100 | $511 | 0.00% | 00.0% | Unchanged |
| Sender Co & Partners, Inc. | 0 | $0 | 0.00% | −28,502−100.0% | Sold out |
| Gyon Technologies Capital Management, LP | 0 | $0 | 0.00% | −12,553−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −1,103−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −799−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −575−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −174−100.0% | Sold out |